140 Prognostic factors of overall survival for patients with recurrent head and neck cancer: a retrospective study

e18504 Background: Nivolumab received FDA approval as monotherapy for the treatment of recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck after failure of platinum-based therapy in 2016. This approval was based on CheckMate 141. When patients ultimately relapse after immunotherapy in the second line setting, third line agents include single agent or combination treatment with a Taxane. Methods: We identified patients with metastatic or recurrent squamous cell head and neck cancer in an Irish hospital who had received Taxane chemotherapy after immunotherapy. We looked at outcomes for these patients including progression free survival (PFS) and overall survival (OS). We then identified a group of patients who received a Taxane following platinum failure in the pre-Nivolumab era to act as a comparator. Our objective was to compare PFS and OS to subsequent Taxane chemotherapy in the era before and after the introduction of Nivolumab as a therapy for platinum refractory head and neck SCC. Results: This retrospective cohort study was made up of 26 patients with metastatic or recurrent head and neck cancer. Primary sites included oropharynx, oral cavity, larynx and nasal cavity squamous cell cancers. The patients had a median age of 56. 13 of these patients identified had progressed on Nivolumab but remained fit for a next line of treatment. Median PFS in this group on Taxane based chemotherapy in the third line setting was 3.8 months. Median OS post progression on Nivolumab was 10 months. One patient remarkably had a complete response to Paclitaxel chemotherapy after progression on previous lines of treatment including immunotherapy, platinum chemotherapy and radiotherapy. We then identified a group of 13 patients with metastatic or recurrent head and neck cancer that had progressed on platinum based therapy in the era before Nivolumab was available. Median PFS after Taxane second line chemotherapy was 2.2 months. Median OS in this group after progressing on platinum treatment was 5.8 months. Conclusions: We set out to share our experience of real-world outcomes for head and neck cancer patients in the Nivolumab era. We found that our patients have shown to have an improved overall survival benefit with subsequent Taxane chemotherapy after immunotherapy compared to those who have not received immunotherapy. All fit patients should be considered for Taxane therapy post failure of Nivolumab.

Download Full-text

A retrospective study of reirradiation for patients with locoregional recurrent head and neck cancer: A single-institution experience

Research in Oncology ◽

10.21608/resoncol.2016.587 ◽

2016 ◽

Vol 12 (1) ◽

pp. 2-9

Author(s):

Dina Salem

Keyword(s):

Head And Neck Cancer ◽

Retrospective Study ◽

Head And Neck ◽

Neck Cancer ◽

Single Institution ◽

Recurrent Head

Download Full-text

Prognostic factors in salvage surgery for recurrent head and neck cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2021.103550 ◽

2021 ◽

pp. 103550

Author(s):

Valentina Lupato ◽

Vittorio Giacomarra ◽

Salvatore Alfieri ◽

Giuseppe Fanetti ◽

Jerry Polesel

Keyword(s):

Systematic Review ◽

Head And Neck Cancer ◽

Prognostic Factors ◽

Head And Neck ◽

Neck Cancer ◽

Salvage Surgery ◽

Meta Analysis ◽

Recurrent Head

Download Full-text

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

Acta Otorhinolaryngologica Italica ◽

10.14639/0392-100x-1246 ◽

2017 ◽

Vol 37 (6) ◽

pp. 458-466

Author(s):

G. Cadoni ◽

L. Giraldi ◽

L. Petrelli ◽

M. Pandolfini ◽

M. Giuliani ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Prognostic Factors ◽

Head And Neck ◽

Retrospective Analysis ◽

Neck Cancer ◽

Hazard Ratio ◽

Single Institution

È stata condotta unanalisi retrospettiva su 482 pazienti con diagnosi di tumore testa-collo arruolati presso l ospedale Agostino Gemelli di Roma. Lassociazione tra fattori demografici, clinici e comportamentali con la overall survival (OS), il rischio di ricorrenza ed il rischio di un secondo tumore primitivo è stata stimata usando gli Hazard Ratio (HR) e gli intervalli di confidenza al 95% (CIs). La OS considerando tutte le sedi tumorali è stata del 60%, mentre considerando le singole sedi tumorali è risultata del 49.0% per il cavo orale, 54.8% per lorofaringe, 50.0% per lipofaringe e 63.4% per la laringe. Unetà avanzata alla diagnosi (HR = 1.04; 95% CI: 1.02-1.05) ed un avanzato stadio del tumore (HR = 2.00; 95% CI: 1.41-2.84) sono risultati fattori significativamente associati con la OS. Il rischio di ricorrenza è risultato associato con il consumo di alcolici (HR = 1.73; 95% CI: 1.00-2.97). Il rischio di sviluppare un secondo tumore primitivo è risutlato associato con uno stadio avanzato del tumore primario (HR = 2.75; 95% CI: 1.39-5.44) e con laver fumato per più di 40 anni (HR = 3.68; 95% CI: 1.10-12.30). In conclusione abbiamo notato che la OS differisce tra le sedi tumorali del tumore testa-collo. Lo stadio tumorale è risultato essere associato sia con la OS che con il rischo di sviluppare un secondo tumore primitivo. Il consumo di alcol e di tabacco sono risultati essere fattori prognostici, rispettivamente, per la ricorrenza e per linsorgenza di un secondo tumore primitivo.

Download Full-text